Drug Type Synthetic peptide |
Synonyms A6 |
Target |
Mechanism LYVE1 antagonists(Hyaluronic acid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Angstrom Bio, Inc.Startup |
Active Organization Angstrom Bio, Inc.Startup |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H62N10O15 |
InChIKeyNJSODKGEFNFGRI-PJYAFMLMSA-N |
CAS Registry220334-14-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 2 | - | Angstrom Bio, Inc.Startup | - |
Small Lymphocytic Lymphoma | Preclinical | US | 01 Feb 2014 | |
Ovarian Cancer | Preclinical | US | 05 Dec 2006 | |
Fallopian Tube Carcinoma | Preclinical | US | 24 May 2004 | |
Peritoneal Neoplasms | Preclinical | US | 07 May 2004 | |
Diabetic Retinopathy | Preclinical | US | - | |
Dystrophy, Macular | Preclinical | US | - |